About this Research Topic
Cancer immunotherapy, an innovative anti-cancer strategy, has been revolutionizing the traditional treatments of cancer. While radiotherapy and chemotherapy are effective, they can damage normal cells and produce severe side effects. Conversely, immunotherapy leverages the body's immune system to attack cancer cells, thus providing higher specificity and fewer side effects. The success of immunotherapies, however, remains limited by our ability to identify and validate effective biomarkers that can predict response and outcome. Accurately profiling these biomarkers is vital for personalizing immunotherapies, enabling more efficacy while minimizing side effects. Therefore, the need to develop novel and comprehensive methods to profile biomarkers for cancer immunotherapy is significant for improving clinical management of the therapy.
This research aims to devise novel, comprehensive methods for analysing biomarkers underlying cancer immunotherapy. These may include, but are not limited to TMB (tumor mutation burden), MSI (microsatellite instability), PD-L1, TGF-beta (Transforming growth factor-beta), circulating tumor DNA, Interleukin 8, etc. More specifically, our objective is to tackle challenges pertaining to biomarker identification, their validation, and application that currently limit the success of immunotherapies. We welcome contributions from experts in diverse disciplines such as oncology, immunology, molecular biology, and bioinformatics. Recent advances in cancer immunotherapy and biomarker research have opened new opportunities for cancer treatment, resulted in better understanding of cancer immune responses, and paved the way for more effective therapeutic strategies. By integrating recent advancements in cancer immunotherapy and biomarker research, we hope to gain a better understanding of the immune response and how it can be modulated for improved therapeutic outcomes.
We welcome original research articles, review papers, systematic reviews/meta-analyses, perspective pieces, and opinion pieces related to the field of cancer immunotherapy. By addressing these themes and paper types, this research topic aims to provide novel and comprehensive approaches for profiling biomarkers underlying cancer immunotherapy and accelerate the development of more effective and personalized immunotherapies for patients with cancer. Content welcome but are not limited to the following studies:
• Novel techniques for biomarker identification and validation
• Integration of multi-modal and multi-omics data for biomarker discovery
• Research on the correlation between biomarkers and patient prognosis
• Application of Biomarkers in predicting and monitoring patients' immune response
• Biomarker-based evaluation of immune checkpoint inhibitors and other novel immunotherapies
• Translational studies bridging bench-to-bedside for biomarker-guided immunotherapy
This research aims to devise novel, comprehensive methods for analysing biomarkers underlying cancer immunotherapy. These may include, but are not limited to TMB (tumor mutation burden), MSI (microsatellite instability), PD-L1, TGF-beta (Transforming growth factor-beta), circulating tumor DNA, Interleukin 8, etc. More specifically, our objective is to tackle challenges pertaining to biomarker identification, their validation, and application that currently limit the success of immunotherapies. We welcome contributions from experts in diverse disciplines such as oncology, immunology, molecular biology, and bioinformatics. Recent advances in cancer immunotherapy and biomarker research have opened new opportunities for cancer treatment, resulted in better understanding of cancer immune responses, and paved the way for more effective therapeutic strategies. By integrating recent advancements in cancer immunotherapy and biomarker research, we hope to gain a better understanding of the immune response and how it can be modulated for improved therapeutic outcomes.
We welcome original research articles, review papers, systematic reviews/meta-analyses, perspective pieces, and opinion pieces related to the field of cancer immunotherapy. By addressing these themes and paper types, this research topic aims to provide novel and comprehensive approaches for profiling biomarkers underlying cancer immunotherapy and accelerate the development of more effective and personalized immunotherapies for patients with cancer. Content welcome but are not limited to the following studies:
• Novel techniques for biomarker identification and validation
• Integration of multi-modal and multi-omics data for biomarker discovery
• Research on the correlation between biomarkers and patient prognosis
• Application of Biomarkers in predicting and monitoring patients' immune response
• Biomarker-based evaluation of immune checkpoint inhibitors and other novel immunotherapies
• Translational studies bridging bench-to-bedside for biomarker-guided immunotherapy
Keywords: cancer immunotherapy, biomarkers, clinical management, novel methods, comprehensive strategies, multi-endpoint research
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
